Cédric Rossi , Guillaume Manson , Amira Marouf , Aurélie Cabannes-Hamy , Emmanuelle Nicolas-Virelizier , Marie Maerevoet , Marion Alcantara , Lysiane Molina , Antony Ceraulo , Marilyne Poirée , Jean Galtier , Nadia Diop , Caroline Delette , Amandine Segot , Sydney Dubois , Agathe Waultier , Sophie Bernard , Robin Noël , Stéphanie Guidez , Milena Kohn , Hervé Ghesquières
{"title":"Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines","authors":"Cédric Rossi , Guillaume Manson , Amira Marouf , Aurélie Cabannes-Hamy , Emmanuelle Nicolas-Virelizier , Marie Maerevoet , Marion Alcantara , Lysiane Molina , Antony Ceraulo , Marilyne Poirée , Jean Galtier , Nadia Diop , Caroline Delette , Amandine Segot , Sydney Dubois , Agathe Waultier , Sophie Bernard , Robin Noël , Stéphanie Guidez , Milena Kohn , Hervé Ghesquières","doi":"10.1016/j.ejca.2024.115073","DOIUrl":null,"url":null,"abstract":"<div><div>Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":7.6000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924012048","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL.
期刊介绍：
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
